The subtle change in the ratio of HIF-1α and HIF-2α in cells, via the dual functions of HAF in hypoxia, might provide a new strategy to develop a combination therapy for renal cell carcinoma. This evidence concerns the gene EPAS1 and hereditary clear cell renal cell carcinoma.